Related Experiment Video
Updated: Jul 3, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
No association between systemic sclerosis and C77G polymorphism in the human PTPRC (CD45) gene
Holger Kirsten1, Mechthild Blume, Frank Emmrich
1Institute of Clinical Immunology and Transfusion Medicine,University of Leipzig, Leipzig, Germany.
The Journal of Rheumatology
|July 18, 2008
Summary
This study investigated the PTPRC C77G variant
Area of Science:
- Genetics
- Immunology
- Rheumatology
Background:
- The PTPRC (CD45) C77G variant (rs17612648) was previously suggested to increase systemic sclerosis (SSc) risk in German Caucasians.
- Systemic sclerosis is a complex autoimmune disease with a significant genetic component.
Purpose of the Study:
- To validate the association between the PTPRC C77G variant and SSc risk in an independent and larger German cohort.
- To assess the variant's role across different SSc subgroups.
Main Methods:
- Genotyping of the PTPRC C77G variant in 171 SSc cases and 179 healthy controls from Germany.
- Subgroup analysis based on sex, autoantibody profiles, and clinical subsets.
- Combined analysis with previously published data.
Main Results:
- No statistically significant association was found between the PTPRC C77G variant and SSc in the overall cohort.
- Subgroup analyses and combined analyses with prior studies also failed to detect a significant association.
- The C77G variant did not demonstrate a link to SSc development in this larger German population.
Conclusions:
- The PTPRC C77G variant is not confirmed as a general and independent risk factor for systemic sclerosis in the German population.
- Further research may be needed to explore other genetic factors contributing to SSc pathogenesis.
- The findings suggest that the initial association reported may not be generalizable or robust.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...